<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640822</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 80190-O22</org_study_id>
    <nct_id>NCT00640822</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds</brief_title>
  <official_title>A Phase 3 Study Comparing an Ointment Containing Calcipotriol 25 mcg/g Plus Hydrocortisone 10 mg g With Tacalcitol 4 mcg/g Ointment and the Ointment Vehicle Alone, All Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and on the Intertriginous Areas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are few therapies suitable for the treatment of psoriasis on the face and skin folds.
      As these areas are sensitive, irritation and other adverse reactions are more common than
      elsewhere on the body. The purpose of the study is to compare the efficacy and safety of once
      daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus
      hydrocortisone 10 mg/g with tacalcitol 4 mcg/g ointment and the ointment vehicle alone in
      patients with psoriasis vulgaris on the face and on the intertriginous ares
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Disease Severity of the Face According to the Investigator's Assessment</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sign Score of the Face</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity Scores for Redness, Thickness and Scaliness of the Face</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Disease Severity of the Intertriginous Areas According to the Investigator's Assessment</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sign Score of the Intertriginous Areas</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Relapse During the Study and Time to Relapse</measure>
    <time_frame>Week 8-16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Rebound During the Study</measure>
    <time_frame>Week 8-16</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">782</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Calcipotriol plus Hydrocortisone ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacalcitol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacalcitol once daily for up to 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcipotriol plus Hydrocortisone ointment vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol plus hydrocortisone ointment vehicle</intervention_name>
    <description>Once daily application for up to 8 weeks</description>
    <arm_group_label>Calcipotriol plus Hydrocortisone ointment vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacalcitol Ointment</intervention_name>
    <description>Once daily application for up to 8 weeks</description>
    <arm_group_label>Tacalcitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol plus hydrocortisone ointment</intervention_name>
    <description>Once daily application for up to 8 weeks</description>
    <arm_group_label>Calcipotriol plus Hydrocortisone ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of psoriasis vulgaris involving the face

          -  Clinical signs of psoriasis vulgaris on the trunk and/or the limbs, or earlier
             diagnosed with psoriasis vulgaris on the trunk and/or the limbs

          -  An extent of psoriatic involvement of the face of at least 10 cm2 (the sum of all
             facial lesions)

          -  Treatment areas (the face and the intertriginous areas) amenable to topical treatment
             with a maximum of 10 g of ointment per day

          -  Disease severity graded as mild, moderate, severe or very severe according to the
             investigator's global assessment of disease severity of the face

        Exclusion Criteria:

          -  Systemic treatments with all other therapies than biologicals, with a potential effect
             on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids,
             immunosuppressants) within the 4-week period prior to randomisation

          -  Systemic use of biological treatments, whether marketed or not, directed against or
             with a potential effect on psoriasis vulgaris (e.g., alefacept, efalizumab,
             etanercept, infliximab, adalimumab) within 3 months prior to randomisation

          -  PUVA therapy or Grenz ray therapy within the 4-week period prior to randomisation

          -  UVB therapy within the 2-week period prior to randomisation

          -  Topical treatment of the face and the intertriginous areas within the 2-week period
             prior to randomisation (use of emollients is allowed on treatment areas during this
             2-week period, but not during the study)

          -  Topical treatment with very potent WHO group IV corticosteroids within the 2-week
             period prior to randomisation

          -  Initiation of or expected changes in concomitant medication that may affect psoriasis
             vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) during
             the study

          -  Systemic treatment with vitamin D preparations above 500 IU per day

          -  Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis

          -  Patients with any of the following conditions present on the treatment area: viral
             (e.g., herpes or varicella) lesions of the skin, fungal and bacterial skin infections,
             parasitic infections, skin manifestations in relation to syphilis or tuberculosis,
             rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae,
             fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds

          -  Other inflammatory skin diseases (e.g., seborrhoeic dermatitis, contact dermatitis and
             cutaneous mycosis) that may confound the evaluation of psoriasis vulgaris on the face
             or on the intertriginous areas

          -  Planned exposure to sun, UVA or UVB that may affect the psoriasis vulgaris during the
             study

          -  Known or suspected severe renal insufficiency or severe hepatic disorders

          -  Known or suspected disorders of calcium metabolism associated with hypercalcemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Fleming, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ninewells Hospital &amp; Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Probity Medical Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital &amp; Medical School</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <results_first_submitted>November 23, 2010</results_first_submitted>
  <results_first_submitted_qc>November 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2010</results_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>1 alpha,24-dihydroxyvitamin D3</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of first subject visit was 5 Mar 2008. Date of last subject visit was 18 Jun 2009. Patients came from hospital outpatient clinics or private practice</recruitment_details>
      <pre_assignment_details>Forty-one subjects were not randomised. Most we screen failures or did not have the required extent of disease or withdrew before randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Calcipotriol Plus Hydrocortisone Ointment</title>
          <description>Calcipotriol Plus Hydrocortisone Ointment once daily for up to 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Tacalcitol Ointment</title>
          <description>Tacalcitol once daily for up to 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Calcipotriol Plus Hydrocortisone Ointment Vehicle</title>
          <description>Calcipotriol Plus Hydrocortisone Ointment vehicle once daily for up to 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="317"/>
                <participants group_id="P3" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="279"/>
                <participants group_id="P2" count="258"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Calcipotriol Plus Hydrocortisone Ointment</title>
          <description>Calcipotriol Plus Hydrocortisone Ointment once daily for up to 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Tacalcitol Ointment</title>
          <description>Tacalcitol once daily for up to 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Calcipotriol Plus Hydrocortisone Ointment Vehicle</title>
          <description>Calcipotriol Plus Hydrocortisone Ointment vehicle once daily for up to 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="322"/>
            <count group_id="B2" value="317"/>
            <count group_id="B3" value="102"/>
            <count group_id="B4" value="741"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="15.5"/>
                    <measurement group_id="B2" value="49" spread="15.5"/>
                    <measurement group_id="B3" value="48.8" spread="14.2"/>
                    <measurement group_id="B4" value="48.5" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8</title>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcipotriol Plus Hydrocortisone Ointment</title>
            <description>Calcipotriol Plus Hydrocortisone Ointment once daily for up to 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tacalcitol Ointment</title>
            <description>Tacalcitol once daily for up to 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Calcipotriol Plus Hydrocortisone Ointment Vehicle</title>
            <description>Calcipotriol Plus Hydrocortisone Ointment vehicle once daily for up to 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="317"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Disease Severity of the Face According to the Investigator's Assessment</title>
        <time_frame>Week 4</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sign Score of the Face</title>
        <time_frame>Week 8</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity Scores for Redness, Thickness and Scaliness of the Face</title>
        <time_frame>Week 8</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Disease Severity of the Intertriginous Areas According to the Investigator's Assessment</title>
        <time_frame>Week 8</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sign Score of the Intertriginous Areas</title>
        <time_frame>Week 8</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Relapse During the Study and Time to Relapse</title>
        <time_frame>Week 8-16</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Rebound During the Study</title>
        <time_frame>Week 8-16</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety analysis set consists of all randomised subjects who received any treatment with trial medication and for whom the presence or confirmed absence of adverse events was available. Two subjects withdrew within the first week of the study and did not apply any study medication so they were excluded from the safety analysis set.</desc>
      <group_list>
        <group group_id="E1">
          <title>Calcipotriol Plus Hydrocortisone Ointment</title>
          <description>Calcipotriol Plus Hydrocortisone Ointment once daily for up to 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Tacalcitol Ointment</title>
          <description>Tacalcitol once daily for up to 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Calcipotriol Plus Hydrocortisone Ointment Vehicle</title>
          <description>Calcipotriol Plus Hydrocortisone Ointment vehicle once daily for up to 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Company acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Torsten Skov</name_or_title>
      <organization>LeoPharma</organization>
      <phone>+4520736294</phone>
      <email>torsten.skov@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

